Caroline Rynn

697 total citations
13 papers, 387 citations indexed

About

Caroline Rynn is a scholar working on Molecular Biology, Oncology and Pharmacology. According to data from OpenAlex, Caroline Rynn has authored 13 papers receiving a total of 387 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Molecular Biology, 6 papers in Oncology and 2 papers in Pharmacology. Recurrent topics in Caroline Rynn's work include Ubiquitin and proteasome pathways (5 papers), Cancer-related Molecular Pathways (4 papers) and Protein Degradation and Inhibitors (3 papers). Caroline Rynn is often cited by papers focused on Ubiquitin and proteasome pathways (5 papers), Cancer-related Molecular Pathways (4 papers) and Protein Degradation and Inhibitors (3 papers). Caroline Rynn collaborates with scholars based in Switzerland, United States and United Kingdom. Caroline Rynn's co-authors include Matthias Wittwer, Prasoon Chaturvedi, Isabelle Walter, Carina Cantrill, Philipp Holzer, Stéphane Ferretti, Keiichi Masuya, Stephan Ruetz, Stefan Stutz and Pascal Furet and has published in prestigious journals such as Cancer Research, Journal of Medicinal Chemistry and Pharmaceutical Research.

In The Last Decade

Caroline Rynn

11 papers receiving 378 citations

Peers

Caroline Rynn

ONCOL

HEMAT

Vivek Kumar Singh India

Keqin Kathy Li China

Yulia Jitkova Canada

Tolou Shadbahr Finland

Weiqiong Zuo China

Estelle G. McLean United Kingdom

Christian T. Meyer United States

Jagannath Pal United States

Sonia Pahwa United States

Vivek Kumar Singh India

Caroline Rynn

304 ×1.1

61 ×0.4

ONCOL

76 ×1.5

HEMAT

47 ×1.0

47 ×1.2

Citations per year, relative to Caroline Rynn Caroline Rynn (= 1×) peers Vivek Kumar Singh

Countries citing papers authored by Caroline Rynn

Since Specialization

Citations

This map shows the geographic impact of Caroline Rynn's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Caroline Rynn with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Caroline Rynn more than expected).

Fields of papers citing papers by Caroline Rynn

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Caroline Rynn. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Caroline Rynn. The network helps show where Caroline Rynn may publish in the future.

Co-authorship network of co-authors of Caroline Rynn

This figure shows the co-authorship network connecting the top 25 collaborators of Caroline Rynn. A scholar is included among the top collaborators of Caroline Rynn based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Caroline Rynn. Caroline Rynn is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

13 of 13 papers shown

Caron, Giulia, Gauri Deshmukh, Andy Pike, et al.. (2025). Finding a needle in the haystack: ADME and pharmacokinetics/pharmacodynamics characterization and optimization towards orally available bifunctional protein degraders. Expert Opinion on Drug Discovery. 20(3). 373–389. 6 indexed citations

Humphreys, Sara C., David O. Nettleton, Colin Phipps, et al.. (2023). Industry Perspective on the Pharmacokinetic and Absorption, Distribution, Metabolism, and Excretion Characterization of Heterobifunctional Protein Degraders. Drug Metabolism and Disposition. 51(7). 792–803. 29 indexed citations

Shaw, Duncan, Simona Cotesta, René Lattmann, et al.. (2023). Design and Synthesis of Inhibitors of the E3 Ligase SMAD Specific E3 Ubiquitin Protein Ligase 1 as a Treatment for Lung Remodeling in Pulmonary Arterial Hypertension. Journal of Medicinal Chemistry. 66(12). 8130–8139. 3 indexed citations

Heinig, Katja, Filippo Sladojevich, Georg Jaeschke, et al.. (2022). Chemical, Analytical and Pharmacokinetic Characterisation of RO7304898, an API Consisting of Two Rapidly Interconverting Diastereoisomers. Pharmaceutical Research. 39(4). 653–667.

Dudal, Sherri, Caterina Bissantz, Antonello Caruso, et al.. (2022). Translating pharmacology models effectively to predict therapeutic benefit. Drug Discovery Today. 27(6). 1604–1621. 8 indexed citations

Rynn, Caroline, et al.. (2022). A translational strategy employing physiologically based modelling to predict the pharmacological active dose of RO7119929, an oral prodrug of a targeted cancer immunotherapy TLR7 agonist. Xenobiotica. 52(8). 855–867.

Cantrill, Carina, et al.. (2020). Fundamental aspects of DMPK optimization of targeted protein degraders. Drug Discovery Today. 25(6). 969–982. 116 indexed citations

Vaupel, Andrea, Philipp Holzer, Stéphane Ferretti, et al.. (2018). In vitro and in vivo characterization of a novel, highly potent p53-MDM2 inhibitor. Bioorganic & Medicinal Chemistry Letters. 28(20). 3404–3408. 16 indexed citations

Forkuo, Arnold Donkor, Charles Ansah, David Pearson, et al.. (2017). Identification of cryptolepine metabolites in rat and human hepatocytes and metabolism and pharmacokinetics of cryptolepine in Sprague Dawley rats. BMC Pharmacology and Toxicology. 18(1). 84–84. 8 indexed citations

10.

Holzer, Philipp, Patrick Chêne, Stéphane Ferretti, et al.. (2016). Abstract 4855: Discovery of NVP-HDM201 - First disclosure of a Next-Generation Mdm2 inhibitor with superior characteristics. Cancer Research. 76(14_Supplement). 4855–4855. 6 indexed citations

11.

Holzer, Philipp, Keiichi Masuya, Pascal Furet, et al.. (2015). Discovery of a Dihydroisoquinolinone Derivative (NVP-CGM097): A Highly Potent and Selective MDM2 Inhibitor Undergoing Phase 1 Clinical Trials in p53wt Tumors. Journal of Medicinal Chemistry. 58(16). 6348–6358. 152 indexed citations

12.

Masuya, Keiichi, Pascal Furet, Stefan Stutz, et al.. (2014). Abstract DDT01-01: Discovery of CGM097 as a novel Mdm2 inhibitor. Cancer Research. 74(19_Supplement). DDT01–1. 2 indexed citations

13.

MacGowan, Alasdair, Caroline Rynn, Mandy Wootton, et al.. (1999). In vitro assessment of colistin's antipseudomonal antimicrobial interactions with other antibiotics. Clinical Microbiology and Infection. 5(1). 32–36. 41 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact